Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback